3R Research Foundation Switzerland - Front page
News


 

de | fr | en   print view

News

A new Chairman of the Administrative Board (December 2013)
On 2 December 2013 the Administrative Board elected Joachim Eder, Member of the Council of States, as Chairman to the Administrative Board. He replaces Christine Egerszegi, Member of the Council of States, who resigned from the Administrative Board.
Administrative Board

A new face on the Administrative Board (December 2013)
On 2 December 2013 the Administrative Board elected Dr. med. vet. Kaspar Jörger, Head of the Division Animal Protection of the (new) Federal Office for Food Safety and Veterinary Affairs to the Administrative Board. He replaces Prof. Hans Wyss, Director of the Federal Veterinary Office, who resigned from the Administrative Board.
Administrative Board

A new face on the Administrative Board (October 2013)
On 31 October 2013 the Administrative Board elected Dr. med. vet. Philippe Bugnon, who works for the Institute of Laboratory Animal Science, University of Zurich, to the Administrative Board. He replaces Silvia Matile-Steiner, who resigned from the Administrative Board.
Administrative Board

Publication of Annual Report for 2012 (June 2013)
On 7 May 2013 the Administrative Board approved the Foundation’s Annual Report for 2012, which describes its activities during last year, as well as the financial statements for 2012. A total amount of Fr. 619,000 was paid out for research projects. Four new projects were approved and the final reports on four projects were received.
Annual Report for 2012 | PDF version

A new face on the Administrative Board (May 2013)
On 7 Mai 2013 the Administrative Board elected Dr. Birgit Ledermann, who works for Novartis Pharma Ltd., Basle (Deputy Corporate Animal Welfare Officer), to the Administrative Board. She replaces Dr. Markus Schmutz, who resigned from Novartis.
Administrative Board

A new face on the Administrative Board (May 2013)
On 7 Mai 2013 the Administrative Board elected Claudia Mertens, dipl. phil. nat., Scientific Adviser of „Zürcher Tierschutz“, Zurich, to the Administrative Board. She replaces Dr. Franz P. Gruber, who resigned from the Administrative Board.
Administrative Board

New Scientific Adviser and Chairman of the Evaluation Committee (February 2013)
The Administrative Board has appointed Prof. Ernst B. Hunziker, head of the Center of Regenerative Medicine for Skeletal Tissues at the University of Berne, to take over as Scientific Adviser and Chairman of the Evaluation Committee on 1 March 2013.
Evaluation Committee

Resignation of Prof. Peter Maier as Scientific Adviser and Chairman of the Evaluation Committee (December 2012)
Prof. Peter Maier retired at the end of 2012, having been involved with the 3R Research Foundation for 12 years. During that time he helped the Foundation develop into an institution that is recognised by academic researchers throughout Europe. The Administrative Board would like to extend their sincerest thanks to Prof. Maier for his fruitful work and wish him every success with his future career as a toxicologist at the University of Zurich.

3R - Still relevant twenty-five years on; 25 years of Funding the 3Rs (December 2012)
3R-Info-Bulletin 50
Prof. Peter Maier, Scientific Adviser of the 3R Research Foundation in Switzerland, reflects on the visibility, activity and future role of the Foundation.
Dr. Stefanie Schindler, an animal welfare expert, assesses the Foundation’s twenty-five years of funding.
To mark the Foundation’s 25th anniversary, the two authors describe the present situation with regard to animal experimentation in Switzerland (awareness of the Foundation’s work, limited funds) and the progress achieved so far concerning reduction und refinement.
In order to prevent an increase in the use of laboratory animals in the field of life sciences, the established research promotion involving live animals should specifically support aspects relevant to the 3R principles. A study is under way to analyse what the 3R Research Foundation has achieved over the past 25 years in various fields through its albeit limited funding; initial results are published.
3R-Info Bulletin 50

Completion of a project (December 2012)
Use of "moribund" stage in the acute fish toxicity test according to OECD guideline 203 and its effect on LC50 values
Dr. Hans Rufli, ecotoxsolutions, Basle, Switzerland
The aim of this project is to define the final ”moribund” stage in the acute toxicity test in fish in order to introduce it as a criterion for interrupting the test under OECD guideline 203. Retrospective analysis of data and protocols from hundreds of toxicity tests carried out on fish has shown that by introducing the “moribund” criterion the suffering of the fish through the acute effects of a test substance could be reduced by up to 92 hours thanks to its earlier removal from the test. By introducing the “moribund” criterion, the LC50 value could be lowered, on average by a factor of 2, in up to half of the experiments. Attempts are now being made, in collaboration with the Swiss Federal Office for the Environment and various EU countries, to get the OECD protocol changed. This would help to achieve a significant reduction in the level of suffering among the fish used in this test.
Project 123-10

Completion of a project (December 2012)
A new in vitro model to study therapeutic approaches to improve spinal cord regeneration and repair after injury
Prof. Roman Chrast, Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland
This project aimed to examine the effect of various substances on spinal cord regeneration in vitro using mouse organotypic longitudinal, sagital slice cultures developed by the project leaders. The research team was also able to induce lesions similar to those seen in multiple sclerosis, thus allowing for functional and structural studies. Using this method it would be possible to avoid a large number of tests on live animals. Comparative in vivo and in vitro studies using potential new medicines remain to be carried out.
Project 121-10

Completion of a project (December 2012)
Development of non-invasive strategies to study spinal cord disease, injury and repair
Prof. Denis Jabaudon, Neuroscience Department, University Medical Centre, University of Geneva, Geneva, Switzerland
In this project, Prof. Jabaudon aimed to develop a method for the non-invasive injection of substances (e.g. plasmids) into the spinal cord of mice without using a surgical procedure. Such a method would result in a lower rate of mortality and less suffering among the laboratory animals used. The research team was able to demonstrate that the high-resolution ultrasound method for positioning the hypodermic needle for cortical injections was equally as accurate as the stereotactic method. On the other hand, the ultrasound method proved to be unsuitable for spinal injections. It was therefore not possible to establish the non-invasive injection method for use in the spinal cord.
Project 120-10

Completion of a project (December 2012)
Engineering of an in vitro hepatocyte tissue system for malaria liver infection research
Dr. Dalu Mancama, Biosciences Division, Systems Biology, CSIR, Pretoria, South Africa
With this project, the researchers aimed to develop a hepatocyte tissue culture system using human liver cells for the purpose of studying the primary infection process of malaria (infection with plasmodium sporozoites isolated from the Anopheles mosquito) and the proliferation of the parasites in cultured liver cells. The ultimate aim would be to develop vaccines, prophylactic medicines and an acute chemotherapy without using laboratory animals. The main stages of the study were successfully completed. The in vitro culture (proliferation) of the asexual stage of Plasmodium falciparum with erythrocytes, the culture of human hepatocytes with sporozoites and the co-culture with infected erythrocytes were all successful. The rate of infection observed was low and was influenced by the culture conditions. Further verification of the results will be carried out.
Project 118-10

Completion of a project (December 2012)
Engineering of a human brain tumor model to replace animal experimentation
Prof. Olivier Preynat-Seauve, Department of Pathology and Immunology, University Medical Centre, University of Geneva, Geneva, Switzerland
The aim of this project was to combine the delicate cell culture models developed by the project leader for brain tissue (engineered neural tissue, ENT, from embryonic stem cells) and glioblastomas (engineered glial tumors, EGT, from human tumor tissue), and thus to develop an in vitro system for studying glioblastomas and characterising their molecular structure. Such a system would replace in vivo methods that cause considerable suffering to the laboratory animals used, in particular in relation to the intracerebral or subcutaneous injection of human tumor cells in immuno-suppressed mice. The team were successful in establishing their in vitro system. Histo-pathological and molecular-biological studies were carried out on the reaction of the EGT transplanted into the ENT. It now remains to examine the various ways in which this model can be used.
Project 115-09

Completion of a project (December 2012)
Generic in vitro evaluation assay for immunological correlates of protection, to replace animal challenge infection
Dr. Artur Summerfield and Dr. Kenneth McCullough, Institute of Virology and Immuno-prophylaxis (IVI), Mittelhäusern, Switzerland
The aim of this project was to provide a reliable and fast in vitro test to replace in vivo testing by which live animals suffer considerably through being exposed to vaccines in order to match a potential vaccine to the current serotype of foot-and-mouth disease virus in the field. The researchers were able to measure a response specific to the virus type in cultures of specialised immune cells. By using genetically modified cells it was possible to further simplify and improve the test. This provides a scientific basis for developing reliable tests based on cell lines. The new test will now be further validated by a European consortium (FMD-DISCONVAC).
Project 113-08
Informations for applicants and project managers

Deadlines

Principal areas for financial support

Instructions Concerning Project Outlines

Instructions concerning the detailed description of project

Form for Project Outlines (Word)

Application Form (Word)

Form for yearly reports (Word)

Guidelines for Awarding Research Grants

Addresses

Additional 3R news


European Consensus Platform for 3R Alternatives to Animal Experimentation


UK National Centre for the Replacement, Refinement and Reduction of Animals in Research


The global clearinghouse for information on alternatives to animal testing


Non-animal Methods for Toxicity Testing


The European Partnership for Alternative Approaches to Animal Testing



TOP